Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Label_Title

Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

A Case Study of Very Long Fatty Acid Dehydrogenase Deficiency Presented by Irritability and Seizures

AlKaabi S. AlKaabi, Ebead R. Ebead, Khames M.Khames*, Amin M. Amin, Ahmed S. Ahmed, Gupta A.Gupta, Marzouk E.Marzouk

ICU Department Zayed Military Hospital Abu Dhabi, UAE

Abstract: This case study presents the clinical course and management of an 18-year-old male patient diagnosed with very long fatty acid dehydrogenase deficiency (VLCADD). The patient exhibited recurrent episodes of rhabdomyolysis accompanied by acute kidney injury (AKI) and elevated liver enzymes. Presented to us by irritability and restlessness and 3 episodes of seizures. The purpose of this case study is to highlight the challenges in diagnosing and managing this rare metabolic disorder and to emphasize the importance of early recognition and intervention to prevent further complications.

Keywords: VLCADD, very long fatty acid dehydrogenase (FAD), rhabdomyolysis, seizure

Received February 01, 2024; Revised March 01, 2024; Accepted March 10, 2024

Citation: AlKaabi S. AlKaabi, Ebead R. Ebead, Khames M.Khames, Amin M. Amin, Ahmed S. Ahmed, Gupta A.Gupta, Marzouk E.Marzouk, A Case Study of Very Long Fatty Acid Dehydrogenase Deficiency Presented by Irritability and Seizures. American Journal of Medical Case Reports, 12 (3). 33-37. January 2024. doi:10.12691/ajmcr-12-3-2

1. Introduction

Very long fatty acid dehydrogenase deficiency “VLCADD” is a rare autosomal recessive disorder characterized by impaired metabolism of fatty acids. Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD, OMIM 201475) is the second most common disorder of inborn errors of fatty acid metabolism; its incidence varies between 1:30,000 and 1:400,000 live births, with some outliers such as Saudi Arabia with reported incidence of 1:3200 and Taiwan with 1:1,400,000. In Europe incidence range from 1:77,000 in Germany and Netherlands to 1:400,000 in Czech Republic. [1,2,3,4,5] Incidence of VLCADD increased after the introduction of an expanded newborn screening program with the use of tandem mass spectrometry (MS/MS) allowing early detection of patients [1,6]. VLCADD is caused by pathogenic variants in the ACADVL gene and is inherited in an autosomal recessive manner, resulting in deficient enzyme in the mitochondrial β-oxidation of long-chain fatty acids. Fatty acids are an important source of energy during prolonged fasting, physical exercise, and febrile infections when the body requires more energy. In VLCADD long-chain fatty acids with chain lengths of 14–20 carbons are not metabolized, which can lead to metabolic crises due to inadequate energy supply. This lack of energy may result in symptoms such as lethargy and hypoglycemia. Fats that are not properly broken down can also build-up and damage tissues in the heart, liver, and skeletal muscles, which can cause the other clinical features observed in people with VLCADD [7]; Very Long Chain Acyl CoA Dehydrogenase Deficiency (VLCADD) - NORD (National Organization for Rare Disorders)].

Patients with “VLCADD” are unable to adequately break down fatty acids for energy production, leading to various clinical manifestations, including recurrent rhabdomyolysis and multi-organ involvement. [8]

There are three forms of VLCAD infant, childhood, and adult. [9,10,11,12]

Symptoms can be mild to serious.

Infant and childhood types of VLCADD may cause periods of illness called Metabolic Crises, or low blood sugar. Some of the first signs of a Metabolic Crisis are:

• Too much sleepiness

• Behavior changes (such as crying for no reason)

• Irritable mood

• Poor appetite

If a Metabolic Crisis is not treated, a patient with VLCADD can develop.

• Breathing problems and seizures

• Coma, sometimes leading to death

• Other problems include enlarged liver, cardiomyopathy and muscle problem.

We present a case of an 18-year-old male patient diagnosed with very long FAD deficiency who experienced recurrent rhabdomyolysis and AKI with increased liver enzymes.

Figure 1. Main stages in carnitine and fatty acid ß-oxidation cycle. Uptake and activation of FA, in gray: FATP, FAT/CD36: fatty acid transporters; AS: acyl-CoA synthetase; Cycling of carnitine to pass the FA to the mitochondrial matrix, in red: OCTN2: carnitine transporter; CPT I: carnitine palmitoyltransferase I; CACT: carnitine-acylcarnitine translocase; CPT II: carnitine palmitoyltransferase II; β-Oxidation spiral, in green: SCAD: short-chain acyl-CoA dehydrogenase; MCAD: medium-chain acyl-CoA dehydrogenase; VLCAD: very long-chain acyl-CoA dehydrogenase; SCEH: short-chain enoyl-CoA hydratase; LCEH: long-chain enoyl-CoA hydratase; HAD (M/SCHAD): 3-hydroxyacyl-CoA dehydrogenase; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase; S/MCKAT: short/medium-chain 3-ketoacyl-CoA thiolase; LCKAT: long-chain 3-ketoacyl-CoA thiolase; MTP: mitochondrial trifunctional protein; MAD: multiple acyl-CoA dehydrogenase; Electron transfer and respiratory chain pathway, in blue: CoQ, CI, CII, CIII, CIV, CV: coenzyme Q and mitochondrial respiratory complexes I, II, III, IV and V. [13]

2. Case Presentation

An 18-year-old male patient presented to the emergency department with a history of recurrent episodes of muscle pain, weakness, and dark urine. Each episode lasted for approximately 2-3 days before resolving spontaneously. The patient reported no significant past medical history or family history of similar symptoms, has past history of subclinical hypothyroidism.

Investigated for myositis by MRI and muscle biopsy all was normal.

Patient admitted to the medical ward in our hospital by same presentation and diagnosed by Rhabdomyolysis associated with AKI and fatigability.

On physical examination, the patient appeared with generalized muscle tenderness. Laboratory investigations revealed elevated serum creatine kinase (CK) levels (24,000 U/L; reference range: 24-170 U/L), myoglobinuria, and acute kidney injury (serum creatinine: 3.8 mg/dL; reference range: 0.6-1.2 mg/dL).

Additionally, liver function tests showed elevated levels of liver enzymes, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Other laboratory parameters, including electrolytes and blood glucose, were within normal ranges

Patient managed by rehydration and discharge after 4 days.

Patient presented again to ED next day after discharge by irritability and restlessness but was conscious managed by dose of diazepam. After few hours patient complained of headache and episode of convulsions that aborted by another dose of diazepam, but he went into status epileptics and severe aspiration and desaturation required intubation and connection to MV and admitted in ICU.

Figure 2. CT Chest at admission

3. Management and Outcome

The patient was admitted to the intensive care unit (ICU)

Patient ventilated in prone position as a case of ARDS for 3 days, monitoring and aggressive management of ARDS, Rhabdomyolysis and AKI. Intravenous fluids were initiated to maintain hydration and prevent renal complications. Sedation and IV Levetiracetam to control seizure

EEG done and epileptic focus excluded

CT, MRV brain done, and venous sinus thrombosis excluded.

Patient improved and successfully extubated after 3 days.

Metabolic disorders especially Fatty acid oxidation disorders highly suspected so the following tests ordered:

• Plasma Acylcarnitine profile

• Plasma total/free carnitine levels

• Urine organic acids

The result came back:

• Tetradecenoyl carnitine(C14:1) elevated 2.15 µmol/L (ref. <0.3µmol/L)

• Tetra dienoyl carnitine (C14:2) elevated 0.56µmol/L (ref. <0.15µmol/L)

• Urine organic acid returned normal.

During the hospital stay, the patient's renal function gradually improved, and CK levels normalized. Liver enzyme levels also decreased to near-normal ranges.

Figure 3. ICU admission lab results

Figure 4. Serial ABG results

Figure 5. Creatine kinase results

Figure 6. Acylcarnitine screening

4. Discussion

FAD deficiency is a rare metabolic disorder that is associated with recurring episodes of rhabdomyolysis, acute kidney injury (AKI), and liver involvement. This ailment is characterized by sporadic muscle pain and weakness in mature individuals. Rhabdomyolysis, a syndrome caused by injury to the skeletal muscle, is a frequently occurring complication of FAD deficiency. It results in the release of potentially hazardous intracellular contents into the bloodstream. Complications arising from rhabdomyolysis encompass acute kidney injury, severe hyperkalemia, and hypovolemic shock. In the case of FAD deficiency, liver involvement is also observable, and the primary approach revolves around metabolic and liver-related interventions. All in all, FAD deficiency is a complex ailment that necessitates meticulous management to prevent complications and ensure optimal outcomes for patients. It is of utmost importance to promptly identify and diagnose the ailment to avert complications and long-term harm to the organs. The treatment mainly revolves around supportive measures during acute episodes, such as intravenous fluid administration and urine alkalization. Long-term management entails adhering to a low-fat, high-carbohydrate diet and avoiding triggers that could provoke rhabdomyolysis.

5. Conclusion

This case emphasizes the significance of considering VLCADD in patients who present with recurrent rhabdomyolysis, AKI, and elevated liver enzymes. Prompt diagnosis and appropriate management are critical for preventing complications and enhancing patient outcomes. Such cases prompt healthcare systems to implement programs for early detection of these genetic diseases in newborns. Further research is necessary to gain a better understanding of the pathophysiology of this rare disorder and to develop targeted therapies for affected individuals.

References

[1]   | A. Boneh et al., “VLCAD deficiency: Pitfalls in newborn screening and confirmation of diagnosis by mutation analysis,” Mol Genet Metab, vol. 88, no. 2, pp. 166–170, Jun. 2006.
[2]   | J. G. Loeber et al., “Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010,” International Journal of Neonatal Screening 2021, Vol. 7, Page 15, vol. 7, no. 1, p. 15, Mar. 2021.
[3]   | M. Lindner, G. F. Hoffmann, and D. Matern, “Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting,” J Inherit Metab Dis, vol. 33, no. 5, pp. 521–526, Oct. 2010.
[4]   | U. Spiekerkoetter et al., “Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop,” J Inherit Metab Dis, vol. 32, no. 4, pp. 498–505, Aug. 2009.
[5]   | G. L. Arnold et al., “A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency,” Mol Genet Metab, vol. 96, no. 3, pp. 85–90, Mar. 2009.
[6]   | J. L. Merritt et al., “Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening,” Mol Genet Metab, vol. 111, no. 4, pp. 484–492, Apr. 2014.
[7]   | N. Leslie and S. Saenz-Ayala, “Very long-chain acyl-coenzyme A dehydrogenase deficiency,” 2022, Accessed: Mar. 05, 2024. [Online]. Available: https://europepmc.org/books/nbk6816
[8]   | I. J. Lawrence Merritt, M. Norris, and S. Kanungo, “Fatty acid oxidation disorders,” Ann Transl Med, vol. 6, no. 24, pp. 181–183, Apr. 2018.
[9]   | J. C. Bleeker et al., “Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency,” J Inherit Metab Dis, vol. 42, no. 1, pp. 159–168, Jan. 2019.
[10]   | E. F. Diekman et al., “Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency,” Genet Med, vol. 17, no. 12, pp. 989–994, Dec. 2015.
[11]   | E. F. Diekman et al., “Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency,” Genetics in Medicine, vol. 17, no. 12, pp. 989–994, Dec. 2015.
[12]   | M. Evans, B. S. Andresen, J. Nation, and A. Boneh, “VLCAD deficiency: Follow-up and outcome of patients diagnosed through newborn screening in Victoria,” Mol Genet Metab, vol. 118, no. 4, pp. 282–287, Aug. 2016.
[13]   | P. Ruiz-Sala and L. Peña-Quintana, “Biochemical Markers for the Diagnosis of Mitochondrial Fatty Acid Oxidation Diseases,” J Clin Med, vol. 10, no. 21, 2021.